Market Closed -
Nasdaq
04:30:01 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
13.94
USD
|
+6.37%
|
|
+1.83%
|
-35.67%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,741
|
4,502
|
2,506
|
2,269
|
1,301
|
838.9
|
-
|
-
|
Enterprise Value (EV)
1 |
2,732
|
2,841
|
763.7
|
996.6
|
547.7
|
335.8
|
508.8
|
365.6
|
P/E ratio
|
-5.4
x
|
7.57
x
|
-5.45
x
|
-4.25
x
|
-2.39
x
|
-2.14
x
|
-2.67
x
|
-4.78
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
545
x
|
4.04
x
|
397
x
|
295
x
|
15
x
|
19.5
x
|
6.36
x
|
2.77
x
|
EV / Revenue
|
398
x
|
2.55
x
|
121
x
|
130
x
|
6.34
x
|
7.82
x
|
3.86
x
|
1.21
x
|
EV / EBITDA
|
-3.87
x
|
4.53
x
|
-1.67
x
|
-1.83
x
|
-0.95
x
|
-0.81
x
|
-1.49
x
|
-1.5
x
|
EV / FCF
|
-5.11
x
|
4.3
x
|
-2.02
x
|
-2.16
x
|
-1.01
x
|
-1.37
x
|
-2.59
x
|
-6.12
x
|
FCF Yield
|
-19.6%
|
23.3%
|
-49.6%
|
-46.3%
|
-98.8%
|
-72.7%
|
-38.6%
|
-16.3%
|
Price to Book
|
3.96
x
|
2.43
x
|
1.45
x
|
1.81
x
|
1.63
x
|
1.39
x
|
1.04
x
|
1.03
x
|
Nbr of stocks (in thousands)
|
51,818
|
52,045
|
58,908
|
59,494
|
60,033
|
60,182
|
-
|
-
|
Reference price
2 |
72.19
|
86.51
|
42.54
|
38.14
|
21.67
|
13.94
|
13.94
|
13.94
|
Announcement Date
|
2/27/20
|
2/24/21
|
2/24/22
|
2/16/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
6.868
|
1,114
|
6.308
|
7.686
|
86.46
|
42.96
|
131.9
|
303.3
|
EBITDA
1 |
-705.8
|
626.6
|
-456.7
|
-545.9
|
-578.5
|
-417
|
-342.5
|
-243.1
|
EBIT
1 |
-708.1
|
624
|
-460.9
|
-547
|
-579.8
|
-425.5
|
-353
|
-213.3
|
Operating Margin
|
-10,310.48%
|
56%
|
-7,306.74%
|
-7,116.69%
|
-670.69%
|
-990.44%
|
-267.56%
|
-70.35%
|
Earnings before Tax (EBT)
1 |
-680.2
|
606.1
|
-457.9
|
-532.8
|
-541.5
|
-397.7
|
-330.1
|
-174.5
|
Net income
1 |
-680.2
|
606.1
|
-457.9
|
-532.8
|
-541.5
|
-396.6
|
-331.8
|
-200.9
|
Net margin
|
-9,904.46%
|
54.4%
|
-7,258.91%
|
-6,931.88%
|
-626.32%
|
-923.13%
|
-251.54%
|
-66.26%
|
EPS
2 |
-13.38
|
11.43
|
-7.800
|
-8.980
|
-9.050
|
-6.522
|
-5.221
|
-2.917
|
Free Cash Flow
1 |
-534.5
|
660.8
|
-378.6
|
-461
|
-541.1
|
-244.2
|
-196.3
|
-59.77
|
FCF margin
|
-7,781.84%
|
59.31%
|
-6,001.17%
|
-5,997.57%
|
-625.92%
|
-568.51%
|
-148.8%
|
-19.71%
|
FCF Conversion (EBITDA)
|
-
|
105.46%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
109.03%
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/24/21
|
2/24/22
|
2/16/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1.642
|
1.582
|
1.501
|
1.739
|
2.865
|
3.294
|
2.474
|
2.716
|
77.97
|
7.902
|
9.225
|
11.61
|
14.48
|
24.42
|
34.21
|
EBITDA
1 |
-125.2
|
-119.4
|
-125.5
|
-140.1
|
-153.6
|
-158.3
|
-174.5
|
-182.9
|
-35.48
|
-118.9
|
-90.1
|
-78.7
|
-72.3
|
-
|
-
|
EBIT
1 |
-125.5
|
-123.2
|
-128.4
|
-141.5
|
-153.9
|
-155.5
|
-170.5
|
-178.2
|
-42.07
|
-117.7
|
-106.9
|
-102.2
|
-97.71
|
-93.25
|
-81.39
|
Operating Margin
|
-7,642.33%
|
-7,787.55%
|
-8,554.76%
|
-8,135.71%
|
-5,371.8%
|
-4,719.79%
|
-6,889.94%
|
-6,562.96%
|
-53.96%
|
-1,489.18%
|
-1,159.05%
|
-880.35%
|
-674.79%
|
-381.93%
|
-237.92%
|
Earnings before Tax (EBT)
1 |
-124.7
|
-122.1
|
-126.3
|
-137.3
|
-147.1
|
-146.8
|
-160.3
|
-201.6
|
-32.71
|
-108.5
|
-99.33
|
-95.17
|
-90.5
|
-80.59
|
-76.58
|
Net income
1 |
-124.7
|
-122.1
|
-126.3
|
-137.3
|
-147.1
|
-146.8
|
-160.3
|
-201.6
|
-32.71
|
-108.5
|
-99.7
|
-95.1
|
-90.53
|
-80.59
|
-76.58
|
Net margin
|
-7,595.13%
|
-7,715.23%
|
-8,411.73%
|
-7,896.66%
|
-5,135.99%
|
-4,457.44%
|
-6,480.4%
|
-7,423.78%
|
-41.95%
|
-1,372.85%
|
-1,080.82%
|
-819.15%
|
-625.18%
|
-330.06%
|
-223.87%
|
EPS
2 |
-2.120
|
-2.070
|
-2.130
|
-2.310
|
-2.470
|
-2.460
|
-2.680
|
-3.370
|
-0.5500
|
-1.800
|
-1.663
|
-1.588
|
-1.513
|
-1.573
|
-1.473
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/3/22
|
8/2/22
|
11/8/22
|
2/16/23
|
5/2/23
|
8/7/23
|
11/7/23
|
2/14/24
|
4/25/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,008
|
1,661
|
1,742
|
1,272
|
753
|
503
|
330
|
473
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-534
|
661
|
-379
|
-461
|
-541
|
-244
|
-196
|
-59.8
|
ROE (net income / shareholders' equity)
|
-75.3%
|
42%
|
-24.1%
|
-35.7%
|
-49.5%
|
-50.1%
|
-30.2%
|
-9.8%
|
ROA (Net income/ Total Assets)
|
-66.8%
|
39.1%
|
-23%
|
-33.5%
|
-45.4%
|
-45.9%
|
-23.5%
|
-6%
|
Assets
1 |
1,018
|
1,551
|
1,992
|
1,591
|
1,193
|
863.8
|
1,410
|
3,351
|
Book Value Per Share
2 |
18.20
|
35.50
|
29.30
|
21.00
|
13.30
|
10.00
|
13.40
|
13.50
|
Cash Flow per Share
2 |
-10.40
|
12.50
|
-6.450
|
-7.760
|
-9.030
|
-4.930
|
-3.560
|
-0.6300
|
Capex
1 |
5.75
|
0.35
|
0.37
|
0.94
|
0.55
|
2.48
|
2.87
|
2.59
|
Capex / Sales
|
83.74%
|
0.03%
|
5.9%
|
12.19%
|
0.64%
|
5.77%
|
2.17%
|
0.85%
|
Announcement Date
|
2/27/20
|
2/24/21
|
2/24/22
|
2/16/23
|
2/14/24
|
-
|
-
|
-
|
Last Close Price
13.94
USD Average target price
22.17
USD Spread / Average Target +59.01% Consensus |
1st Jan change
|
Capi.
|
---|
| -35.67% | 839M | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +6.79% | 14.16B | | +38.61% | 12.63B |
Bio Therapeutic Drugs
|